VIE Viela Bio Inc - Ordinary Shares

27.47
+0.83  (+3%)
Previous Close 26.64
Open 26.84
Price To Book -5.39
Market Cap 1,399,927,788
Shares 50,962,060
Volume 119,804
Short Ratio
Av. Daily Volume 140,800
Stock charts supplied by TradingView

NewsSee all news

  1. Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights

    GAITHERSBURG, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial

  2. Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions

    Viela Bio is eligible to receive an upfront licensing fee of $30 million as well as development and commercialization milestones and payments based, in part, on sales revenue GAITHERSBURG, M.D., Oct. 09, 2019 (GLOBE

  3. Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date June 11, 2020.
Inebilizumab
Neuromyelitis Optica Spectrum Disorder
Phase 2 trial to be initiated 4Q 2019.
Inebilizumab
Kidney transplant desensitization
Pivotal trial to be initiated 1H 2020.
Inebilizumab
Myasthenia gravis
Phase 2 trial to be initiated 4Q 2019.
VIB4920
Sjögren’s syndrome
Phase 2 trial to be initiated 4Q 2019.
VIB4920
Kidney transplant rejection

Latest News

  1. Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights

    GAITHERSBURG, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Viela Bio (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today reported financial

  2. Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions

    Viela Bio is eligible to receive an upfront licensing fee of $30 million as well as development and commercialization milestones and payments based, in part, on sales revenue GAITHERSBURG, M.D., Oct. 09, 2019 (GLOBE

  3. Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Viela Bio, Inc. (NASDAQ:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the